Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
At 72, Kathie Lee Gifford says aging isn’t what she expected. 'The golden years? It’s a lie.’ - 2Russia’s New KVS Drone May Be Designed To Restore Reach In The FPV War
- 3‘Downton Abbey: The Grand Finale’ hits streaming: How to watch, cast info and everything you need to know
- 4Zelensky sees new Russian attack threat from Belarus
- 5Astronomers may have spotted the 1st known 'superkilonova' double star explosion
- 15 skywatching events you won't want to miss in 2026
- Instructions to Upgrade the Proficiency of Your Sunlight powered chargers
- CDC studies show value of nationwide wastewater disease surveillance, as potential funding cut looms
- The most effective method to Remain Ahead in the Most recent Advanced Patterns with a Web based Advertising Degree
- Doritos and Cheetos debut 'NKD' options, without artificial colors or flavors
- Russian authorities threaten WhatsApp with total ban
- Remain Fit: Powerful Wellness and Work-out Schedules for a Better You
- Don't fall for it: These common tourist scams in Rome are easy to avoid if you know what you're looking for
- Horror and fear in West Bank as Israel approves hanging Palestinians convicted of murdering Israelis
